Your browser doesn't support javascript.
loading
Evaluation of 5-(Trifluoromethyl)-1,2,4-oxadiazole-Based Class IIa HDAC Inhibitors for Huntington's Disease.
Stott, Andrew J; Maillard, Michel C; Beaumont, Vahri; Allcock, David; Aziz, Omar; Borchers, Alexander H; Blackaby, Wesley; Breccia, Perla; Creighton-Gutteridge, Gillian; Haughan, Alan F; Jarvis, Rebecca E; Luckhurst, Christopher A; Matthews, Kim L; McAllister, George; Pollack, Scott; Saville-Stones, Elizabeth; Van de Poël, Amanda J; Vater, Huw D; Vann, Julie; Williams, Rachel; Yates, Dawn; Muñoz-Sanjuán, Ignacio; Dominguez, Celia.
Affiliation
  • Stott AJ; Charles River Discovery, Chesterford Research Park, Saffron Walden, Essex CB10 1XL, United Kingdom.
  • Maillard MC; CHDI Management/CHDI Foundation Inc., 6080 Center Drive, Suite 700, Los Angeles, California 90045, United States.
  • Beaumont V; CHDI Management/CHDI Foundation Inc., 6080 Center Drive, Suite 700, Los Angeles, California 90045, United States.
  • Allcock D; Charles River Discovery, Chesterford Research Park, Saffron Walden, Essex CB10 1XL, United Kingdom.
  • Aziz O; Charles River Discovery, Chesterford Research Park, Saffron Walden, Essex CB10 1XL, United Kingdom.
  • Borchers AH; CHDI Management/CHDI Foundation Inc., 6080 Center Drive, Suite 700, Los Angeles, California 90045, United States.
  • Blackaby W; Charles River Discovery, Chesterford Research Park, Saffron Walden, Essex CB10 1XL, United Kingdom.
  • Breccia P; Charles River Discovery, Chesterford Research Park, Saffron Walden, Essex CB10 1XL, United Kingdom.
  • Creighton-Gutteridge G; Charles River Discovery, Chesterford Research Park, Saffron Walden, Essex CB10 1XL, United Kingdom.
  • Haughan AF; Charles River Discovery, Chesterford Research Park, Saffron Walden, Essex CB10 1XL, United Kingdom.
  • Jarvis RE; Charles River Discovery, Chesterford Research Park, Saffron Walden, Essex CB10 1XL, United Kingdom.
  • Luckhurst CA; Charles River Discovery, Chesterford Research Park, Saffron Walden, Essex CB10 1XL, United Kingdom.
  • Matthews KL; Charles River Discovery, Chesterford Research Park, Saffron Walden, Essex CB10 1XL, United Kingdom.
  • McAllister G; Charles River Discovery, Chesterford Research Park, Saffron Walden, Essex CB10 1XL, United Kingdom.
  • Pollack S; Charles River Discovery, Chesterford Research Park, Saffron Walden, Essex CB10 1XL, United Kingdom.
  • Saville-Stones E; Charles River Discovery, Chesterford Research Park, Saffron Walden, Essex CB10 1XL, United Kingdom.
  • Van de Poël AJ; Charles River Discovery, Chesterford Research Park, Saffron Walden, Essex CB10 1XL, United Kingdom.
  • Vater HD; Charles River Discovery, Chesterford Research Park, Saffron Walden, Essex CB10 1XL, United Kingdom.
  • Vann J; Charles River Discovery, Chesterford Research Park, Saffron Walden, Essex CB10 1XL, United Kingdom.
  • Williams R; Charles River Discovery, Chesterford Research Park, Saffron Walden, Essex CB10 1XL, United Kingdom.
  • Yates D; Charles River Discovery, Chesterford Research Park, Saffron Walden, Essex CB10 1XL, United Kingdom.
  • Muñoz-Sanjuán I; CHDI Management/CHDI Foundation Inc., 6080 Center Drive, Suite 700, Los Angeles, California 90045, United States.
  • Dominguez C; CHDI Management/CHDI Foundation Inc., 6080 Center Drive, Suite 700, Los Angeles, California 90045, United States.
ACS Med Chem Lett ; 12(3): 380-388, 2021 Mar 11.
Article in En | MEDLINE | ID: mdl-33738065
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: ACS Med Chem Lett Year: 2021 Document type: Article Affiliation country: Reino Unido
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: ACS Med Chem Lett Year: 2021 Document type: Article Affiliation country: Reino Unido